• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

HTR2C Gene Record

  • Summary
  • Interactions
  • Claims
  • HTR2C 3358 Druggable Genome

    Alternate Names:

    3358
    5-HYDROXYTRYPTAMINE RECEPTOR 2C
    HTR2C
    5-HT1C
    5-HT2C
    5-HTR2C
    5HTR2C
    HTR1C
    312861
    5295
    ENSG00000147246
    OTTHUMG00000022226
    5-HT-2C
    Serotonin receptor 2C
    5-HT-1C
    5-hydroxytryptamine receptor 1C
    P28335
    5HT2C_HUMAN
    PA194
    5-HYDROXYTRYPTAMINE 2C RECEPTOR (5-HT-2C) (SEROTONIN RECEPTOR 2C) (5- HT2C) (5-HTR2C) (5HT-1C). [SOURCE:UNIPROT/SWISSPROT;ACC:P28335]
    5-HT 2C receptor
    T83813

    Gene Info:

    Target Subclass GPCR
    Target Main Class Receptors
    Target Subclass Rhodopsin
    Transmembrane Helix Count 7
    Target Class Receptors
    Human Readable Name G PROTEIN COUPLED RECEPTOR
    Uniprot Evidence 1: Evidence at protein level
    Interpro Short Name 7TM_GPCR_Rhodpsn
    Human Readable Name DRUGGABLE GENOME
    Interpro Type Family
    Uniprot Status Swiss-Prot
    Interpro Acc IPR000276
    Interpro Name GPCR, rhodopsin-like, 7TM
    Gene Biotype PROTEIN_CODING
    (7 More Sources)

    Gene Categories: Category Details

    KINASE
    G PROTEIN COUPLED RECEPTOR
    DRUGGABLE GENOME

    Publications:

    Opgen-Rhein C et al., 2010, Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample., Pharmacogenomics
    Brasch-Andersen C et al., 2011, A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C)., Eur J Clin Pharmacol
    Sanchez C et al., 2014, A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?, Int Clin Psychopharmacol
    Shahid et al., 2009, Asenapine: a novel psychopharmacologic agent with a unique human receptor signature., J. Psychopharmacol. (Oxford)
    Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
    Citrome, 2011, Role of sublingual asenapine in treatment of schizophrenia., Neuropsychiatr Dis Treat
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Kim DH et al., 2009, Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia., Neurotherapeutics
    Adolph O et al., 2012, Promethazine inhibits NMDA-induced currents - new pharmacological aspects of an old drug., Neuropharmacology
    Sharma A et al., 2003, Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird's eye view., Curr Drug Metab
    Johnson et al., 2003, An investigation of the 5-HT2C receptor gene as a migraine candidate gene., Am. J. Med. Genet. B Neuropsychiatr. Genet.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Richelson et al., 2000, Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds., Life Sci.
    Wood et al., 2006, Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade., CNS Neurol Disord Drug Targets
    Sánchez et al., 2000, In-vivo assessment of 5-HT2A and 5-HT2C antagonistic properties of newer antipsychotics., Behav Pharmacol
    Seeger et al., 1995, Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity., J. Pharmacol. Exp. Ther.
    Stahl et al., 2003, The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice., J Clin Psychiatry
    Cates ME, 2003, Ziprasidone--not an option for serotonin syndrome., CMAJ
    Millan et al., 2005, Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade., Psychopharmacology (Berl.)
    Herrick-Davis et al., 2000, Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors., J. Pharmacol. Exp. Ther.
    Cusack et al., 1994, Binding of antidepressants to human brain receptors: focus on newer generation compounds., Psychopharmacology (Berl.)
    Maj et al., 1977, Doxepin as a blocker of central serotonin receptors., Pharmakopsychiatr Neuropsychopharmakol
    Navailles et al., 2006, Clozapine and haloperidol differentially alter the constitutive activity of central serotonin2C receptors in vivo., Biol. Psychiatry
    Sodhi et al., 2005, A rapid new assay to detect RNA editing reveals antipsychotic-induced changes in serotonin-2C transcripts., Mol. Pharmacol.
    Ma X et al., 2014, HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis., Int J Psychiatry Clin Pract
    Houston JP et al., 2012, Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia., J Clin Psychiatry
    Sicard MN et al., 2010, Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis., Pharmacogenomics
    Risselada AJ et al., 2012, Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study., Pharmacogenomics J
    Godlewska BR et al., 2009, Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene., Pharmacogenomics J
    Mulder H et al., 2009, HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study., J Clin Psychopharmacol
    Mulder H et al., 2007, The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia., J Clin Psychopharmacol
    Mulder H et al., 2007, The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study., Pharmacogenomics J
    Horishita et al., 2006, The tramadol metabolite, O-desmethyl tramadol, inhibits 5-hydroxytryptamine type 2C receptors expressed in Xenopus Oocytes., Pharmacology
    Ogata et al., 2004, The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes., Anesth. Analg.
    Canton et al., 1994, Competitive antagonism of serotonin (5-HT)2C and 5-HT2A receptor-mediated phosphoinositide (PI) turnover by clozapine in the rat: a comparison to other antipsychotics., Neurosci. Lett.
    Zhang JP et al., 2016, Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis., Schizophr Bull
    Dos Santos-Júnior A et al., 2016, Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents., Int J Endocrinol
    Correia CT et al., 2010, Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions., Pharmacogenomics J
    Ujike H et al., 2008, Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study., J Clin Psychiatry
    De Luca V et al., 2007, HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis., Hum Psychopharmacol
    Corena-McLeod M, 2015, Comparative Pharmacology of Risperidone and Paliperidone., Drugs R D
    Jandacek, 2005, APD-356 (Arena)., Curr Opin Investig Drugs
    Halford, 2006, Obesity drugs in clinical development., Curr Opin Investig Drugs
    Muramatsu et al., 1988, 5-HT2 antagonists and minaprine block the 5-HT-induced inhibition of dopamine release from rat brain striatal slices., Eur. J. Pharmacol.
    Kodama et al., 1992, Protective effect of minaprine against the abnormal changes of 2-deoxyglucose uptake by rat hippocampal slices induced by hypoxia/hypoglycemia., Jpn. J. Pharmacol.
    Benelli et al., 2004, Influence of mirtazapine on the sexual behavior of male rats., Psychopharmacology (Berl.)
    Millan, Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies., Therapie
    Millan et al., 2000, Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram., Eur. J. Neurosci.
    Meert et al., 1997, Antagonism of meta-chlorophenylpiperazine-induced inhibition of exploratory activity in an emergence procedure, the open field test, in rats., Behav Pharmacol
    Dekeyne et al., 2001, Following long-term training with citalopram, both mirtazapine and mianserin block its discriminative stimulus properties in rats., Psychopharmacology (Berl.)
    Grinshpoon et al., 2000, Beneficial effect of the addition of the 5-HT 2A/2C and alpha2 antagonist mianserin to ongoing haloperidol treatment in drug-resistant chronically hospitalized schizophrenic patients., Eur. Psychiatry
    Theisen et al., 2007, No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation., Pharmacogenomics J.
    Overstreet et al., 2007, Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats., Alcohol. Clin. Exp. Res.
    Bymaster et al., 1999, Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro., Schizophr. Res.
    Zhang et al., 2006, Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms., Biochem. Pharmacol.
    Hertel, 2006, Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action., Synapse
    Brafford MV et al., 2014, Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting., J Adv Pract Oncol
    Hietala et al., 2001, Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist but not antagonist binding to 5-HT2c receptors after chronic treatment., Psychopharmacology (Berl.)
    Lindström et al., 2006, Sertindole: efficacy and safety in schizophrenia., Expert Opin Pharmacother
    Conn et al., 1987, Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors., J. Pharmacol. Exp. Ther.
    Fiorella et al., 1995, The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine., Psychopharmacology (Berl.)
    Marek et al., 1992, A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action., Psychopharmacology (Berl.)
    Pazzagli et al., 1999, Trazodone increases extracellular serotonin levels in the frontal cortex of rats., Eur. J. Pharmacol.
    Balsara JJ et al., 2005, Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent behaviors in rats., Psychopharmacology (Berl)
    Nash et al., 1994, Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors., Neurosci. Lett.
    Lyon et al., 1986, 3,4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors., Psychopharmacology (Berl.)
    Porcelli S et al., 2016, Possible biomarkers modulating haloperidol efficacy and/or tolerability., Pharmacogenomics
    Kroeze et al., 2003, H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs., Neuropsychopharmacology
    Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry
  • LORCASERIN   HTR2C

    Interaction Score: 4.95

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Novel drug target Established target
    Trial Name Lorcaserin

    PMIDs:
    16259227 16625817


    Sources:
    TdgClinicalTrial TTD

  • LORCASERIN HYDROCHLORIDE   HTR2C

    Interaction Score: 1.24

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • MINAPRINE   HTR2C

    Interaction Score: 1.24

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    2975224 1361012 17016423 17139284


    Sources:
    TdgClinicalTrial TEND

  • CHLORPROTHIXENE   HTR2C

    Interaction Score: 0.88

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist

    PMIDs:
    17016423 17139284


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • MIDOMAFETAMINE   HTR2C

    Interaction Score: 0.74

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    7824160 2871581


    Sources:
    TTD

  • VABICASERIN   HTR2C

    Interaction Score: 0.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • PUERARIN   HTR2C

    Interaction Score: 0.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • METHYSERGIDE   HTR2C

    Interaction Score: 0.62

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    12555241 11752352


    Sources:
    TdgClinicalTrial TEND TTD

  • PROPIOMAZINE   HTR2C

    Interaction Score: 0.62

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    17016423 17139284 19110200 22507664 12678691


    Sources:
    TdgClinicalTrial TEND

  • MIRTAZAPINE   HTR2C

    Interaction Score: 0.59

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist
    Direct Interaction yes

    PMIDs:
    14615872 16433010 10762339 9832994 11271412 11752352


    Sources:
    ChemblInteractions TEND TTD

  • TRAZODONE   HTR2C

    Interaction Score: 0.57

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Trial Name trazodone extended release, DDS-04A,Oleptro
    Novel drug target Established target

    PMIDs:
    3039120 7659770 1365657 10594316 15614572


    Sources:
    TdgClinicalTrial

  • AGOMELATINE   HTR2C

    Interaction Score: 0.49

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name agomelatine, AGO178C, S-20098,Valdoxan, Thymanax
    Novel drug target Established target

    PMIDs:
    15289999


    Sources:
    TdgClinicalTrial

  • ZIPRASIDONE   HTR2C

    Interaction Score: 0.48

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    11132243 16918396 11103883 7562537 14728084 14638642


    Sources:
    TEND

  • OLANZAPINE   HTR2C

    Interaction Score: 0.48

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist
    Direct Interaction yes
    Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

    PMIDs:
    16983399 16918396 17624999 10227113 11752352 16336943 16952163 22967772 25152019 19142101 17702092 21121776 19193342 17632216 19997080 20680028 20504252 26880915 27217270 19434072 17016522 25032030


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB

  • SERTINDOLE   HTR2C

    Interaction Score: 0.45

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name Serdolect

    PMIDs:
    11594443 16925508


    Sources:
    TdgClinicalTrial TEND

  • ZIPRASIDONE MESYLATE   HTR2C

    Interaction Score: 0.41

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • QUETIAPINE FUMARATE   HTR2C

    Interaction Score: 0.41

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • VABICASERIN HYDROCHLORIDE   HTR2C

    Interaction Score: 0.41

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CARPHENAZINE MALEATE   HTR2C

    Interaction Score: 0.41

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ZIPRASIDONE HYDROCHLORIDE   HTR2C

    Interaction Score: 0.41

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ELTOPRAZINE   HTR2C

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • LOXAPINE   HTR2C

    Interaction Score: 0.41

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist
    Direct Interaction yes

    PMIDs:
    10991983


    Sources:
    ChemblInteractions

  • NEFAZODONE   HTR2C

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    16433010 11752352


    Sources:
    TTD

  • MIANSERIN   HTR2C

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    11004734


    Sources:
    TdgClinicalTrial TEND

  • PROMAZINE   HTR2C

    Interaction Score: 0.36

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    17016423 17139284 19110200


    Sources:
    TdgClinicalTrial TEND

  • RISPERIDONE   HTR2C

    Interaction Score: 0.36

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist
    Direct Interaction yes

    PMIDs:
    7898773 11132243 27217270 26880915 25152019 22967772 20680028 20504252 19997080 19193342 19142101 17702092 17632216 25943458


    Sources:
    ChemblInteractions PharmGKB

  • TRAMADOL   HTR2C

    Interaction Score: 0.34

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name tramadol,Tridural, Ryzolt
    Trial Name tramadol hydrochloride,Ultram
    Trial Name tramadol extended-release,Raliva ER

    PMIDs:
    16679816 15105221


    Sources:
    TdgClinicalTrial TEND TTD

  • METHIXENE HYDROCHLORIDE   HTR2C

    Interaction Score: 0.31

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CLOZAPINE   HTR2C

    Interaction Score: 0.29

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    16182256 15917433 25152019 22967772 21121776 20680028 20504252 19434072 19142101 17632216 17016522


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • TEDATIOXETINE   HTR2C

    Interaction Score: 0.29

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Lu AA24530
    Novel drug target Established target
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ChemblInteractions TTD

  • QUETIAPINE   HTR2C

    Interaction Score: 0.27

    Interaction Types & Directionality:
    ligand
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Seroquel
    Novel drug target Established target

    PMIDs:
    11132243 17848919 20504252


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • ASENAPINE   HTR2C

    Interaction Score: 0.27

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Asenapine
    Novel drug target Established target

    PMIDs:
    18308814 10592235 21655346


    Sources:
    TdgClinicalTrial

  • AMISULPRIDE   HTR2C

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20504252


    Sources:
    PharmGKB

  • RENZAPRIDE   HTR2C

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name renzapride
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • CYCLOBENZAPRINE HYDROCHLORIDE   HTR2C

    Interaction Score: 0.25

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LOXAPINE HYDROCHLORIDE   HTR2C

    Interaction Score: 0.25

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • OLANZAPINE PAMOATE   HTR2C

    Interaction Score: 0.25

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • TRAZODONE HYDROCHLORIDE   HTR2C

    Interaction Score: 0.25

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • THIETHYLPERAZINE   HTR2C

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TEND

  • LOXAPINE SUCCINATE   HTR2C

    Interaction Score: 0.21

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DOXEPIN   HTR2C

    Interaction Score: 0.21

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Silenor (SO-101)
    Novel drug target Established target

    PMIDs:
    7855217 309138


    Sources:
    TdgClinicalTrial

  • NEFAZODONE HYDROCHLORIDE   HTR2C

    Interaction Score: 0.21

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ESMIRTAZAPINE MALEATE   HTR2C

    Interaction Score: 0.21

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • BIFEPRUNOX   HTR2C

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Established target
    Trial Name bifeprunox, DU127090

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • ESCITALOPRAM   HTR2C

    Interaction Score: 0.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    21614492 24424469


    Sources:
    PharmGKB

  • TRIMIPRAMINE MALEATE   HTR2C

    Interaction Score: 0.18

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • TRIFLUOPERAZINE HYDROCHLORIDE   HTR2C

    Interaction Score: 0.11

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • THIORIDAZINE   HTR2C

    Interaction Score: 0.08

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • THIORIDAZINE HYDROCHLORIDE   HTR2C

    Interaction Score: 0.08

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • HALOPERIDOL   HTR2C

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437 12629531


    Sources:
    PharmGKB

  • Ensembl: ENSG00000147246

    • Version: 101_38

    Alternate Names:
    HTR2C Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TdgClinicalTrial: P28335

    • Version: January-2014

    Alternate Names:
    HTR2C Gene Symbol

    Gene Info:
    Target Class Receptors
    Target Subclass GPCR
    Target Subclass Rhodopsin

    Publications:

  • HopkinsGroom: P28335

    • Version: 11-September-2012

    Alternate Names:
    ENSG00000147246 Ensembl Gene Id
    5HT2C_HUMAN Uniprot Id
    P28335 Uniprot Accession

    Gene Info:
    Uniprot Evidence 1: Evidence at protein level
    Interpro Short Name 7TM_GPCR_Rhodpsn
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME

    Publications:

  • TEND: P28335

    • Version: 01-August-2011

    Alternate Names:
    ENSG00000147246 Ensembl Gene Id
    3358 Entrez Gene Id
    P28335 Uniprot Accession

    Gene Info:
    Target Subclass GPCR
    Target Main Class Receptors
    Target Subclass Rhodopsin

    Publications:

  • RussLampel: ENSG00000147246

    • Version: 26-July-2011

    Alternate Names:
    5-HYDROXYTRYPTAMINE 2C RECEPTOR (5-HT-2C) (SEROTONIN RECEPTOR 2C) (5- HT2C) (5-HTR2C) (5HT-1C). [SOURCE:UNIPROT/SWISSPROT;ACC:P28335] Description
    HTR2C Display Id
    ENSG00000147246 Ensembl Gene Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • PharmGKB: HTR2C

    • Version: 18-August-2020

    Alternate Names:
    PA194 PharmGKB ID

    Gene Info:

    Publications:
    Opgen-Rhein C et al., 2010, Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample., Pharmacogenomics
    Brasch-Andersen C et al., 2011, A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C)., Eur J Clin Pharmacol
    Houston JP et al., 2012, Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia., J Clin Psychiatry

  • TTD: 5-HT 2C receptor

    • Version: 2020.06.01

    Alternate Names:
    HTR2C TTD Gene Abbreviation
    T83813 TTD Target ID

    Gene Info:

    Publications:
    Garfield AS et al., 2009, Pharmacological targeting of the serotonergic system for the treatment of obesity., J Physiol

  • ChemblInteractions: HTR1C

    • Version: chembl_23

    Alternate Names:
    HTR1C GENE_SYMBOL
    HTR2C GENE_SYMBOL
    5-hydroxytryptamine receptor 2C UNIPROT

    Gene Info:

    Publications:

  • HingoraniCasas: ENSG00000147246

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000147246 Gene Symbol
    HTR2C Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • dGene: HTR2C

    • Version: 27-Jun-2013

    Alternate Names:
    3358 Gene ID
    5-HT2C dGene Synonym
    5-HTR2C dGene Synonym

    Gene Info:

    Gene Categories:
    G PROTEIN COUPLED RECEPTOR

    Publications:

  • Pharos: HTR2C

    • Version: 01-February-2022

    Alternate Names:
    5-hydroxytryptamine receptor 2C Gene Name
    P28335 UniProt ID

    Gene Info:

    Gene Categories:
    KINASE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21